We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Inverness Acquires Advantage Diagnostics

By Labmedica staff writers
Posted on 30 Jun 2004
Print article
In a transaction that will expand the company's intellectual property, Inverness Medical Innovations, Inc. (Waltham, MA, USA) has acquired through a merger transaction all of the stock of Advantage Diagnostics Corp. (ADC, Sunnyvale, CA, USA) for U.S.$2.4 million in cash and a pay-off of ADC debt of $210,000.

Avantage Diagnostics is a lateral flow diagnostic company that specializes in rapid test development and component manufacturing. The company was formed in 1998 by Dr. David Charlton, inventor of one of the key families of lateral flow patents central to the rapid diagnostic industry. Advantage Diagnostics recently developed for Inverness' Applied Biotch (ABI) unit a proprietary drugs-of-abuse test system that combines greatly improved test performance and accuracy with increased efficiency in production and lower manufacturing costs. The acquisition eliminates a future royalty stream related to that product line payable by ABI to ADC under a license agreement.

Inverness Medical Innovations is a global developer of diagnostic devices and is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of professional diagnostic and consumer applications, with a focus on women's health, cardiology, and infectious disease.




Related Links:
Inverness Medical Innovations
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.